Establishment of Helixmith Subsidiaries - Neuromyon, Cartexell​.

VM202-CMT(Charcot-Marie-Tooth disease treatment) phase 1/2a initiated in Korea.​

VM202-DPN(Diabetic neuropathy treatment)-Second Phase 3 initiated in U.S.​

Experimental animal facility opened​.

President Yoo Seung-shin Appointed as CEO - Kim Sun-young
& Yoo Seung-shin became Individual Representatives​.

Moved headquarters to new Magok Building, Seoul.

VM202-CLI(Critical Limb Ischemia), initiated phase 3 clinical trials in China
(Beijing Northland Biotech)

Changed name to Helixmith.

Kim Sun-young, became a sole representative as CEO.​

Established Genopis Inc., contract manufacturing organization.​

VM2020 designated as a Regenerative Medicine Advanced Theraphy
(RMAT) by the FDA for treatment of DPN

VM507, Selected as Government Support Research Projects
VM202-PAD(Peripheral Artery Disease), approved in phase 3 clinical trials in China.​​

VM202-ALS (Amyotrophic Lateral Sclerosis), Phase 1/2 clinical trials in US​.

VM202-CAD(Coronary Artery Disease) Launches Phase 2 in Korea.​

VM202-ALS(Amyotrophic Lateral Sclerosis), U.S. FDA fast track designation​.

Technology transfer contract signed by U.S. company Bluebird Bio for CAR-T treatment.​

VM202-PAD(Peripheral Artery Disease), initiated phase 3 clinical trials in U.S.

VM202-DPN(Diabetic Peripheral Neuropathy), initiated phase 3-1 clinical trials in U.S.(VMDN-003)

VM202-CAD(Coronary Artery Disease) for ischemic heart disease,
signed a development catheter supply contract.
VM202-ALS(Amyotrophic Lateral Sclerosis), Selected as the Ministry of
Health and Welfare's Advanced Medical Technology Development Project.​

VM202-ALS(Amyotrophic Lateral Sclerosis), Received orphan drug desingation from FDA
Gongshinbogam®(Health functional food for memory improvement) to be released.​

VM202-ALS(Amyotrophic Lateral Sclerosis) Joint development contract with Reyon Pharmaceuticals Co.Ltd.​

VM202-ALS(Amyotrophic Lateral Sclerosis), Initiated Phase 1/2 clinical trial in U.S.​

Muppin® (Health functional foods to improve articulation and cartilage health) released​.

LAYLA TAB™(Anthritis Treatment) relaeased in Korean market​
VM202-DPN(Diabetic Neuropathy Treatment), Healthcare R&D Project Selection​.

Transferred technology for chronic hepatitis type B vaccines to Reyon Pharmaceutical Co., Ltd. ​

VM202-DPN(Diabetic Neuropathy Treatment), initiated phase 2 clinical trials in Korea​
VM501(Thrombocytopenia Treatment) initiated Phase 3 clinical trials in China​
PG201(Osteoarthritis) Korea's 7th Natural Products New Drug License​.

VM505 (antibody anticancer treatment) Joint development agreement with Pharmaceuticals Co., Ltd.​

VM202-DPN(Diabetic Neuropathy Treatment) Initiated Phase 2 clinical trial (VMDN-002) in the U.S.

PG201(Osteoarthritis), applied for patent authorization in Korea​
VM202-PAD(Peripheral Artery Disease) Initiates Phase II of Clinical Practice.

VM206RY initiated clinical trial phase 1 in Korea

2011 Alex i™ (health functional food for relieving immune hypersensitivity) released in Korean market

VM202-PAD(Peripheral Artery Disease)initiated clinical trials phase 2 in Korea​.

Kim Yong-soo, became a sole representative as CEO.​

Alex® (health functional food for relieving immune hypersensitivity) and Ato Latte® (moisturizer) released
​Heliccer Acquisition and Acquisition, Health Functional Food and New Natural
Products Pipeline secured.​

VM202-PAD (Ischemic retarded disease treatment), initiated phase 2
clinical trials in U.S.
​ Kim Sun-young and Kim Yong-soo became Individual Representatives.​

VM202-CAD (Healthy Heart Disease Therapy), initiated clinical trial
phase 1/2 in U.S.​
VM202-DPN (Diabetic Neuropathy Therapy),initiated clinical trial
phase 1/2 in U.S.​
PG102(Improvement of immune hypersensitivity), obtained individual
certification from the Ministry of Food and Drug Safety

Selected as BioStar Project by Ministry of Knowledge Economy

Signed an MOU with Cobra Biologics, UK.

VM202-PAD(Peripheral Artery Disease) initiated clinical trial phase 1 in China.​

VM206(anticancer gene therapy vaccine), technology transfer to Reyon Pharmaceutical Co., Ltd.​

Signed a contract with Korea Institute of Biotechnology to introduce targeted cancer treatment
technology​.

Signed a contract with Yonsei University to introduce selective tumor killing adenovirus technology​.

VM106(Chronic Granulomatous Disease Therapy) initiated clinical trials phase I/II in Korea.

VM202-CAD(Coronary Artery Disease) initiated clinical trial phase 1 in U.S.​

VM202RY(Ischemic Coronary Artery Disease) initiated clinical trial phase 1 in Korea.

Exclusive Sales Agreement with Takara Bio, Japan​.

VM106(Chronic Granulomatous Disease Therapy), joint development of Yuhan Corp.
​ Forming a Strategic Solidarity Agreement with Japan's Takara Bio Company​

Listed on the KOSDAQ

VM501 (Thrombocytopenia Treatment), technology transfer to GC Pharma.​

Technology Transfer of Retroviral Vector to Takara Bio, Japan​.

Signed a Joint Research Agreement with Yuhan Corporation​.

Signed Cross licensing agreement with Beijing Northland, China​.

VMDA-3601(Icshemic foot disease treatment), initiated clinical trials phase 2 in Korea​
VM202RY (Heptic coronary artery disease treatment),
technology transfer to Reyon Pharmaceutical Co., Ltd.​

Initiated consignment manufacturing of recombinant retrovirus​

VMDA-3601(Icshemic foot disease treatment), initiated clinical trial phase 1 in Korea​.

Investment of $6 Million from Takara Shuzo, Japan​.

Establishment of joint venture VioTech Ltd with Oxford Biomedica, UK​

Company renamed to Viromed​.

Seoul Regional Small and Medium Business
Administration's certification of venture businesses​.

Export of Retroviral Vector to Takara Shuzo, Japan​

Technology Export to Oxford Biomedica, UK​

Enactment of Green Cross Service Research Agreement​

Established as Byromedica Pacific Co., Ltd.​